Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects.
Shringi SharmaXavier PepinJean CheungLianqing ZhengHua WeiDanielle TownsleyDavid HanMichal MajewskiJoseph A WareJames MannVeerendra MunugalavadlaLouise SheridanPriti PatelAshok GuptaHelen TomkinsonPublished in: British journal of clinical pharmacology (2022)
Acala-NG with or without a PPI is safe and well-tolerated without impeding bioavailability.
Keyphrases